Unum Therapeutics to Present at Upcoming Investor Conference
November 15 2019 - 7:30AM
Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage
biopharmaceutical company focused on developing curative cell
therapies for cancer, today announced its participation in the
following upcoming investor conference:
- Piper Jaffray 31st Annual Healthcare Conference, New
York Date: December 5, 2019, New York,
NYPresentation time: 12:10 p.m.
ETPresenter: Chuck Wilson, Ph.D., President and
Chief Executive Officer
The presentation will be webcast live here and
archived for approximately 90 days.
About Unum TherapeuticsUnum
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing curative cell therapies to treat a broad range of
cancer patients. Unum’s novel proprietary technologies include
Antibody-Coupled T cell Receptor (ACTR), an autologous engineered
T-cell therapy that combines the cell-killing ability of T cells
and the tumor-targeting ability of co-administered antibodies to
exert potent antitumor immune responses, and Bolt-On Chimeric
Receptor (BOXR), designed to improve the functionality of
engineered T cells by incorporating a “bolt-on” transgene to
overcome resistance of the solid tumor microenvironment to T cell
attack. Unum has multiple programs in Phase 1 clinical and
preclinical testing, including; ACTR707 used in combination with
trastuzumab in adult patients with HER2+ advanced cancer and used
in combination with rituximab in adult patients with r/r NHL; and
BOXR1030 expressing the GOT2 transgene and targeting GPC3+ solid
tumor cancers. The Company is headquartered in Cambridge, MA.
Follow Unum Therapeutics on social media:
@UnumRx, and LinkedIn.
Investor Contact: Stephanie Ascher,
212-362-1200 stephanie@sternir.com
Media Contact: Lissette Steele,
202-930-4762 lsteele@vergescientific.com
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024